Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $482,000.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the sale, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $0.15 during midday trading on Wednesday, reaching $237.56. 615,345 shares of the company traded hands, compared to its average volume of 991,333. The firm has a market cap of $14.90 billion, a PE ratio of -11,872.06, a PEG ratio of 0.43 and a beta of 0.27. The stock’s 50-day simple moving average is $204.80 and its 200-day simple moving average is $181.71. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in JAZZ. Vestal Point Capital LP bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at about $127,344,000. Goldentree Asset Management LP bought a new position in shares of Jazz Pharmaceuticals in the third quarter valued at about $149,597,000. Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Jazz Pharmaceuticals by 160.2% in the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after buying an additional 715,361 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in shares of Jazz Pharmaceuticals by 258.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after buying an additional 395,000 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JAZZ. Leerink Partners lifted their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. TD Cowen lifted their price objective on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Sanford C. Bernstein began coverage on Jazz Pharmaceuticals in a report on Thursday, May 21st. They set a “market perform” rating and a $229.00 price objective for the company. Finally, Wells Fargo & Company lifted their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.